Document is current
Any future updates will be listed below
-
Authors
Yaron, Jordan R. https://orcid.org/0000-0002-4133-474X
Ambadapadi, Sriram https://orcid.org/0000-0001-6542-4259
Zhang, Liqiang https://orcid.org/0000-0002-8808-8996
Chavan, Ramani N.
Tibbetts, Scott A.
Keinan, Shahar https://orcid.org/0000-0001-8703-901X
Varsani, Arvind https://orcid.org/0000-0003-4111-2415
Maldonado, Juan https://orcid.org/0000-0002-2322-9620
Kraberger, Simona
Tafoya, Amanda M.
Bullard, Whitney L.
Kilbourne, Jacquelyn
Stern-Harbutte, Alison
Krajmalnik-Brown, Rosa
Munk, Barbara H.
Koppang, Erling O.
Lim, Efrem S. https://orcid.org/0000-0002-3397-9310
Lucas, Alexandra R.
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (1R01AI100987-01A1, 1RC1HL100202)
U.S. Department of Health & Human Services | National Institutes of Health
American Heart Association (17GRNT33460327)
University of Florida (00115070)
- License Information
-
More Information
Article History
Received: 1 August 2019
Accepted: 22 January 2020
First Online: 11 February 2020
Competing interests
: ARL is a listed inventor on issued patents US20060122115A1 and US7419670B2 on the therapeutic uses of Serp-1, and on patent application US20180319868A1 on the therapeutic uses of Serp-1-derived RCL peptides. ARL and JRY are listed inventors on provisional patent application 62/792,201 and PCT/US20/13398 on microbiome effects in inflammatory vasculitis. There are no other competing interests.
